Genprex Inc Stock Price, News & Analysis

Genprex, Inc. has entered into an exclusive licensing agreement with the University of Pittsburgh, allowing access to innovative gene therapy technologies for treating Type 1 and Type 2 diabetes. This agreement grants Genprex exclusive rights to a patent application for GPX-003, aimed at rejuvenating beta cells, while GPX-002 targets Type 1 diabetes by transforming alpha cells into insulin-producing cells. This marks the third technology license for Genprex this year, enhancing its intellectual property portfolio and diabetes therapy initiatives.

Genprex (GNPX) announced that researchers from the University of Pittsburgh will present preclinical data on its gene therapy for Type 1 diabetes at the ATTD 2023 conference from February 22-25 in Berlin, Germany. The gene therapy aims to transform pancreatic alpha cells into beta-like cells producing insulin, potentially offering long-term solutions for diabetes patients. The presentation is expected to highlight the innovative infusion process using an adeno-associated virus vector. This research supports the therapeutic potential of Genprex's novel approach in changing diabetes treatment.

Genprex, Inc. (NASDAQ: GNPX) announced an exclusive license agreement with the University of Pittsburgh, enhancing its gene therapy capabilities for Type 1 diabetes. This agreement grants worldwide access to technology that modulates autoimmunity by transforming macrophages. The technology complements Genprex's existing diabetes therapies, potentially improving outcomes for over 37 million U.S. diabetes patients. Previous successes include significant blood glucose restoration in diabetic mouse models, with promising results expected in non-human primates. CEO Rodney Varner emphasized the strategic importance of expanding their intellectual property portfolio.

Genprex, Inc. (GNPX) announced the approval from its Safety Review Committee (SRC) to advance to the third and final cohort in the Phase 1 dose escalation of the Acclaim-1 clinical trial for REQORSA® in combination with Tagrisso® to treat late-stage non-small cell lung cancer (NSCLC). This decision confirms the drug's favorable safety profile, following prior FDA Fast Track Designation in 2020. The trial aims to evaluate toxicity and efficacy, with expectations to complete patient enrollment in early 2023.

Genprex, Inc. (NASDAQ: GNPX) will present its gene therapies for cancer and diabetes at the RHK 2022 Disruptive Growth Conference on December 6, 2022, at 2:40 p.m. ET in New York City. Catherine Vaczy, Executive Vice President and Chief Strategy Officer, will share insights on the company's innovative therapies, including the ONCOPREX® delivery system for cancer treatment and a new gene therapy approach for diabetes. Investors can engage in Q&A and one-on-one meetings after the presentation.

Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, is set to participate in several investor and industry conferences during October 2022. Key events include the Dawson James Securities Annual Small Cap Growth Conference on October 12, where Catherine Vaczy will present, and the Immuno-Oncology Summit, also on October 12, featuring Dr. Mark Berger. Additional presentations at BIO Europe and LD Micro Main Event XV will showcase their innovative therapies targeting cancer and diabetes. For more details, visit Genprex's website.

Genprex, a clinical-stage gene therapy company, will present its innovative therapies for cancer and diabetes at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. CFO Ryan Confer will provide a virtual overview accessible on-demand starting September 12 at 7:00 a.m. ET. The company’s lead product, REQORSA™, is being evaluated for lung cancer therapies, supported by the ONCOPREX® Nanoparticle Delivery System. The presentation will be recorded for future viewing on Genprex's website.

Genprex, Inc. (GNPX) announced that the USPTO granted U.S. Patent No: 11,278,592 B2, covering methods for using REQORSA Immunogene Therapy in combination with immune checkpoint inhibitors until 2038. This patent is crucial for protecting their therapy involving Keytruda^® for treating non-small cell lung cancer (NSCLC). The ongoing Acclaim-2 Phase 1/2 clinical trial evaluates REQORSA with Keytruda in patients whose cancer progressed after Keytruda treatment, with the Phase 1 portion set to enroll up to 30 patients by mid-2023.

Genprex (NASDAQ: GNPX) announced the Safety Review Committee's approval to advance the Acclaim-1 Phase 1/2 trial of REQORSA™ in combination with Tagrisso® for late-stage non-small cell lung cancer (NSCLC). This decision follows a review of the first cohort, highlighting REQORSA's safety profile. The trial aims to determine the maximum tolerated dose, with enrollment expected to complete the Phase 1 by year-end.

The SRC's decision marks a significant milestone for Genprex, supporting its goal of providing innovative therapies for patients with limited options.